Prescience Point Announces Withdrawal of Its Slate of Nominees to MiMedx's Board
Prescience Point Capital Management has withdrawn its nominees for the MiMedx Group, Inc. (NASDAQ: MDXG) Board of Directors ahead of the Annual Meeting set for May 27, 2021. The firm believes its activism has led to significant improvements in corporate governance and a focus on enhancing shareholder value. Key governance proposals include lowering the special meeting ownership threshold from 50% to 25% and de-staggering the Board. Prescience Point remains a long-term stakeholder, emphasizing that MiMedx shares are undervalued, and encouraging shareholders to support the proposed changes.
- Prescience Point's activism led to corporate governance enhancements at MiMedx.
- Proposals to lower special meeting threshold and de-stagger Board will empower shareholders.
- Management has improved communication about the potential of Amniofix.
- There are ongoing issues that need urgent address for MiMedx to reach its full potential.
BATON ROUGE, La., May 4, 2021 /PRNewswire/ -- Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately
Prescience Point believes that its activism and research efforts have raised awareness of the need for positive change and led to significant enhancements in corporate governance, improved investor relations and a greater focus on enhancing shareholder value at MiMedx, making it unnecessary to pursue further actions to reconstitute the Board at the present time.
Prescience Point is encouraged that the Company has adopted Prescience Point's proposed governance changes. If the proposal to reduce the minimum ownership threshold to call a special meeting from
Prescience Point believes that the MiMedx board of directors and management team has now begun to improve the Company's public messaging and engagement with shareholders—at the Company's first quarter 2021 earnings call on April 29, 2021, MiMedx management finally provided shareholders with more expansive information about the tremendous promise of Amniofix. Prescience Point was also pleased to hear management state during the earnings call that it would focus on organic growth rather than add-on acquisitions which, as Prescience Point has previously stated, would have been an extremely misguided and value destructive use of shareholder capital. Prescience Point hopes that these recent positive changes were not just in reaction to its public campaign, and that, going forward, the Company will continue to focus on fixing its many lingering issues.
Prescience Point remains a long-term stockholder of MiMedx, and has been the owner of over 8 million shares for more than two years. Prescience Point continues to believe that MiMedx shares are grossly undervalued, and that the Company has an extremely bright future.
Prescience Point has published a presentation on its website, which outlines the many issues that MiMedx still needs to address with urgency to complete its transformation into a best-in-class biopharmaceutical company. Prescience Point encourages all MiMedx shareholders to read the presentation and to make their voices heard if the necessary changes outlined in the presentation are not addressed by the Company over the coming months.
"We believe that Prescience Point's efforts during our campaign have led MiMedx's board of directors and management team to propose positive corporate governance changes at the Annual Meeting and begin a concerted investor relations effort that has resulted in greater engagement with shareholders. While still imperfect, these actions constitute steps in the right direction," said Eiad Asbahi, Founder and Managing Partner of Prescience Point.
"Thanks to our efforts, we believe that MiMedx is a much more investable and shareholder-friendly company today than it was prior to the initiation of our campaign. Therefore, with the greater flexibility that would be afforded to shareholders if the MiMedx corporate governance changes are adopted, we believe ending our campaign now is in the best interests of all shareholders, rather than enter into a negotiated settlement agreement with MiMedx that would likely restrict us from adding to our investment in the Company and prevent us from running a campaign in the future," added Mr. Asbahi.
"We have been and will continue to be a champion of MiMedx. We will closely monitor the Company to make sure management and the Board continue to implement the changes we have pushed for in our campaign, and, if necessary, will take further actions to ensure that the Company is on the right path to creating value for all of its shareholders," Mr. Asbahi said.
DISCLAIMER
This material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. In addition, the discussions and opinions in this press release are for general information only and are not intended to provide investment advice. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are "forward-looking statements," which are not guarantees of future performance or results, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained in this press release that are not historical facts are based on current expectations, speak only as of the date of this press release and involve risks that may cause the actual results to be materially different. Certain information included in this material is based on data obtained from sources considered to be reliable. No representation is made with respect to the accuracy or completeness of such data, and any analyses provided to assist the recipient of this presentation in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should also not be viewed as factual and also should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and subject to revision without notice. Prescience Point disclaims any obligation to update the information herein and reserves the right to change any of its opinions expressed herein at any time as it deems appropriate.
About Prescience Point Capital Management
Prescience Point Capital Management is a research-focused, catalyst-driven investment firm that seeks to earn superior risk-adjusted returns uncorrelated to the broader market. Unlike traditional investment strategies, we are unconstrained and can opportunistically invest globally, across asset classes, industry verticals and capital structures.
Whether investing in misunderstood distressed assets, creating value through shareholder activism, or uncovering fraud, we seek to capitalize on opportunities that others miss or fall outside the rigid mandates of most investment firms. Our uniqueness resides in our unconventional thinking, deep research, intellectual curiosity and willingness to go against the prevailing wisdom. The firm was founded by investor Eiad Asbahi in 2009 and is headquartered in Baton Rouge, LA. Follow @PresciencePoint.
View original content:http://www.prnewswire.com/news-releases/prescience-point-announces-withdrawal-of-its-slate-of-nominees-to-mimedxs-board-301283766.html
SOURCE Prescience Point Capital Management
FAQ
What is the significance of Prescience Point withdrawing its nominees for MDXG?
When is the MiMedx Annual Meeting scheduled?
What governance changes is Prescience Point advocating for MiMedx?
Why does Prescience Point believe MDXG shares are undervalued?
What improvements have been made in MiMedx's communications?
